{
  "company": {
    "ticker": "REGN",
    "name": "Regeneron Pharmaceuticals Inc.",
    "category": [
      "Biotech"
    ],
    "sector": "Healthcare",
    "subCategory": "Biotech",
    "cik": "0000872589"
  },
  "reports": [
    {
      "filing": {
        "accessionNumber": "0000872589-25-000028",
        "filingDate": "2025-10-28",
        "reportDate": "2025-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/regn-20250930.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "stable",
        "revenue": 1587.7,
        "netIncome": 1460,
        "operatingCashFlow": 3808.2,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 764.8,
        "marketShareMention": "Defending EYLEA patent through multiple legal proceedings",
        "customerConcentration": 79,
        "geographicBreakdown": {
          "US": 90,
          "RestOfWorld": 10
        },
        "capexAmount": 649.7,
        "capexGrowth": null,
        "partnerships": [
          "Sanofi collaboration",
          "Bayer collaboration",
          "Hansoh Pharmaceuticals licensing agreement",
          "Sanofi",
          "Bayer",
          "Hanosh Pharmaceutical Group Company Limited",
          "Sonoma Biotherapeutics Inc"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Multiple patent litigation proceedings",
          "Department of Justice investigations"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Regeneron delivered strong quarterly results with robust revenue and net income, driven by key product sales and collaborative partnerships. The company continues to defend its intellectual property through extensive patent litigation while maintaining a positive financial outlook.",
        "keyQuotes": [
          "Continued strong performance across our product portfolio",
          "Successfully defending our intellectual property through strategic legal proceedings"
        ],
        "marketData": {
          "priceOnEarningsDate": 562.27001953125,
          "priceAfter7Days": 583.239990234375,
          "priceChangePercent": 3.729519621303502,
          "managementToneScore": 100,
          "earningsBeatScore": 50,
          "priceActionScore": 65,
          "guidanceAccuracyScoreWeighted": 75,
          "compositeSentimentScore": 65,
          "compositeSentiment": "bullish"
        }
      },
      "quarter": "Q3 2025",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2025,
        "fiscalQuarter": 3,
        "fiscalYear": 2025,
        "quarter": "Q3 2025",
        "reportDate": "2025-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000872589-25-000019",
        "filingDate": "2025-08-01",
        "reportDate": "2025-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/regn-20250630.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 1631,
        "netIncome": 1391.6,
        "operatingCashFlow": 2189.5,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 481.9,
        "marketShareMention": "Multiple patent litigation cases to protect EYLEA market share",
        "customerConcentration": 76,
        "geographicBreakdown": {
          "US": 75,
          "RestOfWorld": 25
        },
        "capexAmount": 448.3,
        "capexGrowth": null,
        "partnerships": [
          "Sanofi collaboration",
          "Bayer collaboration",
          "Hansoh Pharmaceuticals licensing agreement",
          "Sanofi",
          "Bayer",
          "Hanosh Pharmaceutical Group Company Limited"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Ongoing Department of Justice investigations",
          "Patent litigation challenges"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Regeneron delivered strong Q2 2025 financial performance with robust revenue and net income. The company continues to defend its key drug EYLEA through multiple patent litigation cases and maintains strategic collaborations with Sanofi and Bayer.",
        "keyQuotes": [
          "The company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies",
          "Sanofi is generally responsible for funding 80% to 100% of agreed-upon development costs"
        ],
        "marketData": {
          "priceOnEarningsDate": 525,
          "priceAfter7Days": 538.1099853515625,
          "priceChangePercent": 2.4971400669642856,
          "managementToneScore": 100,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 75,
          "compositeSentimentScore": 62,
          "compositeSentiment": "bullish"
        }
      },
      "quarter": "Q2 2025",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2025,
        "fiscalQuarter": 2,
        "fiscalYear": 2025,
        "quarter": "Q2 2025",
        "reportDate": "2025-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001804220-25-000022",
        "filingDate": "2025-04-29",
        "reportDate": "2025-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/regn-20250331.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "stable",
        "revenue": 3028.7,
        "netIncome": 808.7,
        "operatingCashFlow": 1045.1,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 831.3,
        "marketShareMention": "Regeneron continues to maintain strong market positioning in ophthalmology and immunology markets",
        "customerConcentration": 76,
        "geographicBreakdown": {
          "US": 60,
          "ROW": 40
        },
        "capexAmount": 229.3,
        "capexGrowth": null,
        "partnerships": [
          "Sanofi collaboration",
          "Bayer collaboration",
          "Sanofi",
          "Bayer"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Ongoing patent litigation for EYLEA",
          "Department of Justice investigations"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Regeneron delivered strong Q1 2025 financial results with robust revenue growth driven by Dupixent and continued profitability. The company maintains a positive outlook despite ongoing patent litigation challenges.",
        "keyQuotes": [
          "Our core business strategy is to maintain a strong foundation in scientific research and drug development using our proprietary technologies",
          "We continue to advance as an integrated, multi-product biotechnology company"
        ],
        "marketData": {
          "priceOnEarningsDate": 634.22998046875,
          "priceAfter7Days": 572.780029296875,
          "priceChangePercent": -9.688906715897954,
          "managementToneScore": 100,
          "earningsBeatScore": 50,
          "priceActionScore": 15,
          "guidanceAccuracyScoreWeighted": 75,
          "compositeSentimentScore": 50,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q1 2025",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2025,
        "fiscalQuarter": 1,
        "fiscalYear": 2025,
        "quarter": "Q1 2025",
        "reportDate": "2025-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001804220-25-000011",
        "filingDate": "2025-02-05",
        "reportDate": "2024-12-31",
        "form": "10-K",
        "url": "https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-20241231.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "not_provided",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "expanding",
        "revenue": 3990,
        "netIncome": null,
        "operatingCashFlow": null,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": 74,
        "geographicBreakdown": {
          "US": 76,
          "International": 24
        },
        "capexAmount": null,
        "capexGrowth": null,
        "partnerships": [
          "Sanofi",
          "Bayer",
          "Roche",
          "Sonoma Biotherapeutics",
          "Alnylam Pharmaceuticals",
          "Intellia Therapeutics",
          "Checkmate Pharmaceuticals",
          "Besse Medical",
          "McKesson Corporation"
        ],
        "supplyChainStatus": "tight",
        "regulatoryHeadwinds": [
          "Medicare Drug Price Negotiation Program",
          "Medicare Inflation Based Rebates",
          "Medicare Part D Program Redesign"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "neutral",
        "overallSentiment": "neutral",
        "summary": "Regeneron faces increasing competition and regulatory challenges, particularly for its key products EYLEA and Dupixent. The company continues to expand its workforce and relies heavily on collaborations with Sanofi and Bayer.",
        "keyQuotes": [
          "We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent.",
          "Attracting, developing, and retaining skilled and experienced employees is crucial to our ability to compete effectively."
        ],
        "marketData": {
          "priceOnEarningsDate": 712.3300170898438,
          "priceAfter7Days": 730.2999877929688,
          "priceChangePercent": 2.522702998890823,
          "managementToneScore": 50,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 52,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q4 2024",
      "quarterInfo": {
        "calendarQuarter": 4,
        "calendarYear": 2024,
        "fiscalQuarter": 4,
        "fiscalYear": 2024,
        "quarter": "Q4 2024",
        "reportDate": "2024-12-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001804220-24-000040",
        "filingDate": "2024-10-31",
        "reportDate": "2024-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/872589/000180422024000040/regn-20240930.htm"
      },
      "insights": {
        "guidanceTone": "confident",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 1946.4,
        "netIncome": 1340.6,
        "operatingCashFlow": 3157.7,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 627.2,
        "marketShareMention": "Patents and litigation suggest strong market position in ophthalmology and biologics",
        "customerConcentration": 75,
        "geographicBreakdown": {
          "US": 80,
          "RestOfWorld": 20
        },
        "capexAmount": 556.3,
        "capexGrowth": null,
        "partnerships": [
          "Sanofi",
          "Bayer",
          "Roche",
          "McKesson Corporation",
          "Besse Medical",
          "Sonoma Biotherapeutics",
          "Alnylam Pharmaceuticals"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Multiple patent litigation proceedings",
          "DOJ investigations regarding marketing practices"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Regeneron delivered strong quarterly performance with robust revenue and net income growth. The company continues to defend its key drug patents and maintain strategic collaborations while facing some regulatory scrutiny.",
        "keyQuotes": [
          "Continued strength in EYLEA and collaboration revenues",
          "Successful patent defense strategies across multiple geographies"
        ],
        "marketData": {
          "priceOnEarningsDate": 1051.239990234375,
          "priceAfter7Days": 996.0499877929688,
          "priceChangePercent": -5.249990768435434,
          "managementToneScore": 90,
          "earningsBeatScore": 50,
          "priceActionScore": 25,
          "guidanceAccuracyScoreWeighted": 75,
          "compositeSentimentScore": 52,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q3 2024",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2024,
        "fiscalQuarter": 3,
        "fiscalYear": 2024,
        "quarter": "Q3 2024",
        "reportDate": "2024-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001804220-24-000028",
        "filingDate": "2024-08-01",
        "reportDate": "2024-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/872589/000180422024000028/regn-20240630.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "stable",
        "revenue": 1918.6,
        "netIncome": 1432.3,
        "operatingCashFlow": 1866.5,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 586,
        "marketShareMention": null,
        "customerConcentration": 75,
        "geographicBreakdown": {
          "US": 80,
          "ROW": 20
        },
        "capexAmount": 314.4,
        "capexGrowth": null,
        "partnerships": [
          "Sanofi",
          "Bayer",
          "Roche",
          "McKessoner Corporation",
          "Sonoma Biotherapeutics Inc"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Patent litigation for EYLEA and other products",
          "Department of Justice investigations"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Regeneron delivered strong quarterly performance with revenue of $1.92B and net income of $1.43B, driven by continued growth in key products like EYLEA. The company maintains a robust pipeline and strategic collaborations while navigating ongoing patent litigation.",
        "keyQuotes": [
          "Our core business strategy is to maintain a strong foundation in basic scientific research and discovery-enabling technologies",
          "We continue to advance as an integrated, multi-product biotechnology company"
        ],
        "marketData": {
          "priceOnEarningsDate": 1057.02001953125,
          "priceAfter7Days": 1052.25,
          "priceChangePercent": -0.4512705003794848,
          "managementToneScore": 100,
          "earningsBeatScore": 50,
          "priceActionScore": 45,
          "guidanceAccuracyScoreWeighted": 75,
          "compositeSentimentScore": 59,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q2 2024",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2024,
        "fiscalQuarter": 2,
        "fiscalYear": 2024,
        "quarter": "Q2 2024",
        "reportDate": "2024-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001804220-24-000017",
        "filingDate": "2024-05-02",
        "reportDate": "2024-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/872589/000180422024000017/regn-20240331.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 3145,
        "netIncome": 722,
        "operatingCashFlow": 1512.5,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 532.2,
        "marketShareMention": "Continued strong performance across key product lines like EYLEA, Dupixent, and Libtayo",
        "customerConcentration": 75,
        "geographicBreakdown": {
          "US": null,
          "ROW": null
        },
        "capexAmount": 133.9,
        "capexGrowth": null,
        "partnerships": [
          "Sanofi collaboration for antibody development",
          "Bayer partnership for EYLEA commercialization",
          "Alnylam collaboration for RNA therapeutics",
          "Sanofi",
          "Bayer",
          "Alnylam Pharmaceuticals",
          "Roche",
          "Sonoma Biotherapeutics"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Ongoing patent litigation for EYLEA and other products",
          "Department of Justice investigations into patient assistance programs"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Regeneron delivered stable financial performance in Q1 2024, with consistent revenues and solid net income. The company continues to leverage its diverse product portfolio and strategic collaborations while managing ongoing legal and regulatory challenges.",
        "keyQuotes": [
          "Our core business strategy is to maintain a strong foundation in basic scientific research and discovery-enabling technologies",
          "Regeneron is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases"
        ],
        "marketData": {
          "priceOnEarningsDate": 969.3099975585938,
          "priceAfter7Days": 938.47998046875,
          "priceChangePercent": -3.180614784485405,
          "managementToneScore": 70,
          "earningsBeatScore": 50,
          "priceActionScore": 35,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 48,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q1 2024",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2024,
        "fiscalQuarter": 1,
        "fiscalYear": 2024,
        "quarter": "Q1 2024",
        "reportDate": "2024-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001804220-24-000009",
        "filingDate": "2024-02-05",
        "reportDate": "2023-12-31",
        "form": "10-K",
        "url": "https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "weak",
        "headcountTrend": "stable",
        "revenue": null,
        "netIncome": null,
        "operatingCashFlow": null,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": 76,
        "geographicBreakdown": null,
        "capexAmount": null,
        "capexGrowth": null,
        "partnerships": [
          "Sanofi",
          "Bayer",
          "Alnylam Pharmaceuticals",
          "Roche",
          "Intellia",
          "Sonoma Biotherapeutics",
          "BARDA",
          "Decibel Therapeutics",
          "Checkmate Pharmaceuticals"
        ],
        "supplyChainStatus": "tight",
        "regulatoryHeadwinds": [
          "Medicare Drug Price Negotiation Program",
          "Medicare Inflation Based Rebates",
          "Medicare Part D Program Redesign"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "defensive",
        "overallSentiment": "bearish",
        "summary": "Regeneron faces significant headwinds from potential Medicare drug pricing reforms, biosimilar competition for EYLEA, and increasing regulatory complexity. The company remains substantially dependent on EYLEA and Dupixent, with concentrated customer base and weak pricing power.",
        "keyQuotes": [
          "Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of others",
          "We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent"
        ],
        "marketData": {
          "priceOnEarningsDate": 905,
          "priceAfter7Days": 902.8800048828125,
          "priceChangePercent": -0.234253604109116,
          "managementToneScore": 5,
          "earningsBeatScore": 50,
          "priceActionScore": 45,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 44,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q4 2023",
      "quarterInfo": {
        "calendarQuarter": 4,
        "calendarYear": 2023,
        "fiscalQuarter": 4,
        "fiscalYear": 2023,
        "quarter": "Q4 2023",
        "reportDate": "2023-12-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001804220-23-000031",
        "filingDate": "2023-11-02",
        "reportDate": "2023-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/872589/000180422023000031/regn-20230930.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "unknown",
        "headcountTrend": "unknown",
        "revenue": 3362.7,
        "netIncome": 1007.8,
        "operatingCashFlow": 3504.3,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 417.3,
        "marketShareMention": null,
        "customerConcentration": 77,
        "geographicBreakdown": null,
        "capexAmount": 467.2,
        "capexGrowth": null,
        "partnerships": [
          "Sanofi",
          "Bayer",
          "Roche",
          "Alnylam",
          "Sonoma",
          "Decibel",
          "Alnylam Pharmaceuticals",
          "Sonoma Biotherapeutics",
          "BARDA",
          "US Government",
          "Decibel Therapeutics",
          "Checkmate Pharmaceuticals",
          "McKesson Corporation"
        ],
        "supplyChainStatus": "unknown",
        "regulatoryHeadwinds": [
          "Patent infringement proceedings",
          "Department of Justice investigations"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Regeneron delivered solid quarterly performance with $3.36B in revenue and $1.01B in net income. The company continues to manage multiple strategic collaborations across pharmaceuticals while navigating complex legal and regulatory challenges.",
        "keyQuotes": [
          "Continuing to expand collaboration partnerships across multiple therapeutic areas",
          "Maintaining strong financial performance despite ongoing patent and regulatory proceedings"
        ],
        "marketData": {
          "priceOnEarningsDate": 818.030029296875,
          "priceAfter7Days": 831.8200073242188,
          "priceChangePercent": 1.685754499647979,
          "managementToneScore": 70,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 54,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q3 2023",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2023,
        "fiscalQuarter": 3,
        "fiscalYear": 2023,
        "quarter": "Q3 2023",
        "reportDate": "2023-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001804220-23-000023",
        "filingDate": "2023-08-03",
        "reportDate": "2023-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/872589/000180422023000023/regn-20230630.htm"
      },
      "insights": {
        "guidanceTone": "confident",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 3158.1,
        "netIncome": 968.4,
        "operatingCashFlow": 2390,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 497.3,
        "marketShareMention": null,
        "customerConcentration": 76,
        "geographicBreakdown": {
          "US": null,
          "ROW": null
        },
        "capexAmount": 291.2,
        "capexGrowth": null,
        "partnerships": [
          "Sanofi",
          "Bayer",
          "Roche",
          "Alnylam",
          "Sonoma Biotherapeutics",
          "Alnylam Pharmaceuticals",
          "Checkmate Pharmaceuticals",
          "McKesson Corporation",
          "Besse Medical"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Patent litigation for EYLEA and Praluent",
          "Department of Justice investigations"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Regeneron delivered strong Q2 2023 financial results with revenues of $3.16 billion and net income of $968.4 million. The company maintains a robust pipeline and continues to invest in R&D while facing some patent and regulatory challenges.",
        "keyQuotes": [
          "Our core business strategy is to maintain a strong foundation in basic scientific research and discovery-enabling technologies",
          "Our objective is to continue to advance as an integrated, multi-product biotechnology company"
        ],
        "marketData": {
          "priceOnEarningsDate": 718.5399780273438,
          "priceAfter7Days": 692.4500122070312,
          "priceChangePercent": -3.6309692735453694,
          "managementToneScore": 90,
          "earningsBeatScore": 50,
          "priceActionScore": 35,
          "guidanceAccuracyScoreWeighted": 75,
          "compositeSentimentScore": 55,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q2 2023",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2023,
        "fiscalQuarter": 2,
        "fiscalYear": 2023,
        "quarter": "Q2 2023",
        "reportDate": "2023-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0001804220-23-000016",
        "filingDate": "2023-05-04",
        "reportDate": "2023-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/872589/000180422023000016/regn-20230331.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "stable",
        "revenue": 3162.1,
        "netIncome": 817.8,
        "operatingCashFlow": 1367.6,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 512.8,
        "marketShareMention": null,
        "customerConcentration": 77,
        "geographicBreakdown": {
          "US": 70,
          "ROW": 30
        },
        "capexAmount": 178.2,
        "capexGrowth": null,
        "partnerships": [
          "Sonoma Biotherapeutics collaboration for T reg therapies",
          "Ongoing collaborations with Sanofi, Bayer, Roche",
          "Sanofi",
          "Bayer",
          "Roche",
          "Sonoma Biotherapeutics",
          "Celltrion Inc",
          "Apotex Inc"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Patent challenges for EYLEA and other products",
          "Department of Justice investigations"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Regeneron delivered strong Q1 2023 financial results with robust revenue of $3.16 billion and net income of $817.8 million. Key products like Dupixent and Libtayo continue to show growth, while the company maintains a diversified portfolio and strategic collaborations.",
        "keyQuotes": [
          "Our core business strategy is to maintain a strong foundation in basic scientific research and discovery-enabling technologies",
          "Our objective is to continue to advance as an integrated, multi-product biotechnology company"
        ],
        "marketData": {}
      },
      "quarter": "Q1 2023",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2023,
        "fiscalQuarter": 1,
        "fiscalYear": 2023,
        "quarter": "Q1 2023",
        "reportDate": "2023-03-31"
      },
      "analyzedSuccessfully": true
    }
  ],
  "totalFetched": 12,
  "successfulAnalyses": 11,
  "lastUpdated": "2025-11-26T06:17:07.221Z"
}